Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a Single Phase 3 Immuno-bridging Trial ATLANTA, GA - July 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, ...

Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.

GeoVax is expecting gross proceeds of about $8.5 million, which it will use for working capital and general corporate purposes. The company is developing an MVA vaccine for mpox, ...

ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against ...

Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology ...

10,000- participant randomized Phase 2 b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate to an approved vaccine against COVID-19 under BARDA's Clinical Studies Network.

In January, GeoVax raised $10 million for the same clinical trials. The $20 million will be used to accelerate three ongoing clinical trials by the company for Covid-19 vaccines and cancer treatments.

GeoVax’s product pipeline includes three ongoing clinical trials for which the funding will largely be used. How Atlanta took a leading role in Covid-19 vaccine research Atlanta, Chinese ...

GeoVax, Inc. ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...

GeoVax's stock (GOVX) has gained 389% in the month to date, rallying ever since the World Health Organization declared mpox a public health emergency of international concern last Wednesday.

An experimental vaccine developed by GeoVax Labs Inc , opens new tab succeeded in promoting development of antibodies that target two different sites on the virus in a small pilot study and has ...